Pulmonary Toxicity

Pulmonary toxicity is injury to the lungs caused by drugs, inhaled chemicals, gases, or particulates. Because the entire cardiac output passes through the lungs and their large surface meets inhaled air directly, the respiratory system is exposed to toxicants by both the bloodstream and the airways, and drug-induced lung disease can mimic many other respiratory conditions.

Definition

Pulmonary toxicity is structural or functional injury to the respiratory system — airways, alveoli, interstitium, or pulmonary vasculature — caused by exposure to a drug, inhaled gas, particulate, or other chemical.

Scope

This topic covers the dual routes of pulmonary exposure, the main patterns of drug- and chemical-induced lung injury — interstitial and inflammatory disease, edema, and airway injury — representative agents, and the diagnostic challenge of attributing lung disease to a drug. It is a reference and educational entry, not clinical guidance.

Core questions

• Why are the lungs exposed to toxicants by both inhalation and the bloodstream?
• What patterns of lung injury do drugs and inhaled chemicals produce?
• Why is drug-induced lung disease difficult to diagnose?
• Which agents are recognised causes of pulmonary toxicity?

Key concepts

• Drug-induced interstitial lung disease
• Dual blood and air exposure
• Oxidant lung injury
• Hypersensitivity and eosinophilic reactions
• Pulmonary fibrosis
• Diagnosis of exclusion

Mechanisms

The lungs are uniquely exposed: they receive the whole cardiac output, so blood-borne toxicants reach them in full, and their vast alveolar surface contacts inhaled gases and particles directly. Injury takes several patterns, including interstitial inflammation and fibrosis, diffuse alveolar damage and non-cardiogenic edema, hypersensitivity and eosinophilic reactions, and airway injury. Mechanisms include direct oxidant damage to alveolar cells — as with high-concentration oxygen or certain drugs — and immune-mediated reactions. Because no test is specific, drug-induced lung disease is often a diagnosis of exclusion, recognised by a compatible pattern and a temporal link to exposure (Schwaiblmair et al., 2012; Klaassen, 2018).

Clinical relevance

Pulmonary toxicity is an important adverse effect of several drug classes and of occupational and environmental inhalation exposures, and it is considered when new respiratory disease appears in someone taking a potentially pneumotoxic drug. This entry explains how lung toxicity is understood and classified; it is not a basis for individual diagnosis or treatment decisions.

Epidemiology

A large and growing number of drugs have been associated with interstitial and other forms of lung injury, but because drug-induced lung disease is a diagnosis of exclusion with no specific confirmatory test, its true frequency is uncertain and probably under-recognised (Schwaiblmair et al., 2012).

History

Drug-induced lung disease was characterised through case series and pharmacovigilance over the second half of the twentieth century, as agents such as certain cytotoxic and antiarrhythmic drugs were linked to interstitial lung injury. Curated registries of pneumotoxic drugs later helped systematise the field by cataloguing reported associations (Schwaiblmair et al., 2012).

Debates

How can drug-induced lung disease be reliably attributed to a drug?

Because there is no specific confirmatory test and the imaging and pathological patterns overlap with other lung diseases, attributing interstitial or other lung injury to a particular drug rests on clinical judgement and exclusion, leaving its frequency and diagnosis uncertain.

Key figures

• Martin Schwaiblmair
• Philippe Camus

Seminal works

• schwaiblmair-2012

Frequently asked questions

Why are the lungs exposed to so many toxicants?

The entire output of the heart passes through the lungs, so blood-borne chemicals reach them completely, and their large alveolar surface is in direct contact with inhaled air, exposing them to gases and particulates as well.

Why is drug-induced lung disease hard to diagnose?

There is no specific test for it, and its imaging and tissue patterns overlap with many other lung diseases, so it is usually a diagnosis of exclusion based on a compatible pattern and a temporal link to the drug.